Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2020 4
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.
Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Macherla S, et al. Among authors: bulumulle a. Int J Mol Sci. 2018 Nov 7;19(11):3505. doi: 10.3390/ijms19113505. Int J Mol Sci. 2018. PMID: 30405053 Free PMC article. Review.
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Fessas P, et al. Among authors: bulumulle a. J Immunother Cancer. 2020 Aug;8(2):e001033. doi: 10.1136/jitc-2020-001033. J Immunother Cancer. 2020. PMID: 32868393 Free PMC article.
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Sharma R, et al. Among authors: bulumulle a. Hepatol Commun. 2022 Jul;6(7):1776-1785. doi: 10.1002/hep4.1927. Epub 2022 Apr 28. Hepatol Commun. 2022. PMID: 35481940 Free PMC article.
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Fessas P, et al. Among authors: bulumulle a. Liver Cancer. 2021 Oct 8;10(6):583-592. doi: 10.1159/000519108. eCollection 2021 Nov. Liver Cancer. 2021. PMID: 34950181 Free PMC article.
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Sehgal K, et al. Among authors: bulumulle a. Clin Lung Cancer. 2021 May;22(3):e379-e389. doi: 10.1016/j.cllc.2020.05.028. Epub 2020 Jun 5. Clin Lung Cancer. 2021. PMID: 32653295 Free PMC article.
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.
Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Pinato DJ, et al. Among authors: bulumulle a. J Immunother Cancer. 2020 Oct;8(2):e000726. doi: 10.1136/jitc-2020-000726. J Immunother Cancer. 2020. PMID: 33028690 Free PMC article.
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Pinato DJ, et al. Among authors: bulumulle a. Eur J Cancer. 2021 Nov;157:140-152. doi: 10.1016/j.ejca.2021.08.020. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34508996
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Pinato DJ, et al. Among authors: bulumulle a. Cancers (Basel). 2020 Jul 10;12(7):1862. doi: 10.3390/cancers12071862. Cancers (Basel). 2020. PMID: 32664319 Free PMC article.